scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products designed to reduce healthcare costs and improve health outcomes. Its lead product, FUROSCIX (furosemide injection) 80 mg/10 mL for subcutaneous use, is indicated for treatment of congestion due to fluid overload in adult patients with chronic heart failure. The company’s programs emphasize subcutaneous, self-administration of IV‑strength treatments in heart failure and infectious disease. Proceeds from the announced financings will be used to repay existing debt and to fund activities related to the ongoing commercialization of FUROSCIX and expansion of outpatient care. The company discloses a history of significant operating losses, expects to incur significant and increasing losses, and notes its credit facility places restrictions on its operating and financial flexibility. scPharmaceuticals was founded in 1999. scPharmaceuticals develops a portfolio of pharmaceutical products for subcutaneous delivery using a proprietary patch pump to convert drugs that currently require intravenous or intramuscular injections into subcutaneous formulations. Its lead products include Furoscix, the first subcutaneous formulation of furosemide, and a subcutaneous formulation of ceftriaxone. The furosemide formulation is intended to enable convenient anytime/anywhere use, for example in outpatient settings instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration aims to eliminate the need for peripherally inserted central catheters and their associated complications and costs. The company is led by founder, president and CEO Pieter Muntendam, MD. scPharmaceuticals also has an antibiotic pipeline it plans to advance alongside its commercial product efforts. scPharmaceuticals is developing a drug/device combination centered on the sc2Wear patch pump to enable subcutaneous delivery of medicines traditionally given by IV. The system uses a micropiston pump technology engineered by Swiss devicemaker Sensile Medical to provide a constant stream of drug from a wearable device. The company is targeting both heart failure and infectious disease indications and in November launched a pivotal trial administering the antibiotic ceftriaxone subcutaneously to compare against IV delivery. scPharmaceuticals is a Massachusetts startup. Financially, a regulatory filing shows it has raised $3.6 million of a proposed $7.5 million financing in what reporting describes as a bridge round. The company previously closed a $16 million Series A in 2014 with participation from 5AM Ventures, Gilde Healthcare Partners and Lundbeckfond Ventures. scPharmaceuticals is a biopharmaceutical company based in Lexington, Massachusetts, developing pharmaceutical products for subcutaneous delivery. It is developing drug-device combination products, including a novel furosemide-based product enabling subcutaneous delivery. It is also developing a cephalosporin antibiotic drug-device combination intended to provide subcutaneous administration where currently only intramuscular and intravenous options exist. The company intends to use the Series A proceeds to further develop its first two pharmaceutical products and its associated drug delivery technology. Leadership includes Bertram Pitt, MD, Professor of Medicine Emeritus at the University of Michigan, and Pieter Muntendam, MD, President and CEO. It closed a $16.0M Series A venture financing co-led by 5AM Ventures and Lundbeckfond Ventures.

Total raised

$65M

Funding rounds

4

Latest round

Series B

Latest activity

Jan 2017